Ceasing down Pseudomonas aeruginosa Invasiveness in A Mouse Burn Wound Sepsis Model by Recombinant OprF
,
Abstract
Background: Bacterial infections in burn and wound patients are common and difficult to control. The aim of the current study was to evaluate the ability of full length OprF to elicit the production of protective IgG in mice burn wound sepsis model against P. aeruginosa infection.Methods: OprF protein was expressed and purified by Ni-NTA. The purified protein as used to immunize BALB/c mice. The antibody raised against OprF was confirmed by ELISA and evaluated by immunoblot analysis. After burn and bacterial challenge, mortality rate was monitored in the control and immunized mice groups. Bacterial quantity in skin, blood, spleen and liver was evaluated to study spread or inhibition of the infection.
Results: Immunization of mice with OprF brought about a significant rise in anti-OprF sera titer. Protection was imparted in the immunized group resulting in 100% survival against 1000 fold LD50 challenge with P. aeruginosa. The antiserum against OprF was able to significantly inhibit the systemic spread of P. aeruginosa infection from the infection site to internal organs.
Conclusions: The results suggest that anti-P. aeruginosa OprF antibodies elicited in burn wound sepsis model by active immunization are protective against infection with P. aeruginosa, and provide a rational for further development of the vaccine for prevention against P. aeruginosa infection in burn patients.
Macedo JLSd, Santos JB. Predictive factors of mortality in burn patients. Revista do Instituto de Medicina Tropical de Sao Paulo 2007; 49: 365-70.2. Alp E, Coruh A, Gunay GK, et al. Risk factors for nosocomial infection and mortality in burn patients: 10 years of experience at a university hospital. J Burn Care & Res 2012; 33: 379-85.
Rodgers GL, Mortensen Joel, Fisher MC,et al. Predictors of infectious complications after burn injuries in children. Ped Infect Dis J 2000; 19: 990-5.
Armour AD, Shankowsky HA, Swanson T, et al. The Impact of Nosocomially-Acquired Resistant Pseudomonas aeruginosa infection in a burn unit. J Trauma Inj Infect Crit Care 2007; 63: 164-71.
Abdel RA, Hafez SF, Abdelhakam SM, et al. Antimicrobial resistant bacteria among health care workers in intensive care units at Ain Shams University Hospitals. J Egypt Soc Parasitol 2010; 40: 71-83.
Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance-Whats dosing got to do with it. Crit care Med 2008; 36: 2433-40.
Agnihotri N, Gupta V, Joshi RM. Aerobic bacterial isolates from burn wound infections and their antibiograms GC; a five-year study. Burns 2004; 30: 241-3.
Wager B, Faudry E, Wills T, et al. Current Fluctuation Analysis of the PopB and PopD Translocon Components of the Pseudomonas aeruginosa Type III Secretion System. Biophys J 2013; 104:1445-55.
Weimer ET, Ervin SE, Wozniak DJ, et al.Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 2009;27: 6762-9.
Mahar P, Padiglione AA, Cleland H, et al.Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.Burns 2010; 36: 1228-33.
Japoni A, Alborzi A, Kalani M, et al. Susceptibility patterns and cross- resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 2006; 32: 343-7.
Lai Z, Kimmel R, Petersen S, et al. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.Vaccine 2005; 23: 3264-71.
Kaloshin AA, Gatypova EV, Mikhailova NA. Obtaining recombinant forms of the outer membrane protein F of Pseudomonas aeruginosa and assessment of their immunogenic properties . Appl Biochem Microbiol 2011; 47: 780-8.
Neely AN, Holder IA. A murine model with aspects of clinical relevance for the study of antibiotic-induced endotoxin release in septic hosts. J Endotoxin Res 1996; 3: 229-35.
Lee NG, Jung SB, Ahn BY, et al.Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine 2000; 18:1952-61.
Baumann U, Mansouri E, von Specht BU.Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.Vaccine 2004; 22: 840-7.
Price BM, Galloway DR, Baker NR, et al.Protection against Pseudomonas aeruginosa Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of P. peruginosa. Infect Immun 2001; 69: 3510-5.
Bumann D, Behre C, Behre K, et al.Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010; 28: 707-13.
Saha S, Takeshita F, Sasaki S, et al.Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 2006;24: 6240-9.
Duchesne R, Bouffartigues E, Oxaran V, et al. Proteomic approaches of SigX functions in Pseudomonas aeruginosa outer membrane composition. J Proteomics 2013;94: 451-9.
Mansouri E, Blome-Eberwein S, Gabelsberger J, et al. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol Med Microbiol 2003; 37:161-6.
| Files | ||
| Issue | Vol 3 No 1-2 (2014) | |
| Section | Original Articles | |
| Keywords | ||
| Pseudomonas aeruginosa Opr Infection Burn Vaccine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
